Israel’s OphthaliX updates on clinical developments and strategic plans

9 June 2014

Israel-based OphthaliX (OTCqb: OPLI), a majority-owned subsidiary of biotech firm Can-Fite BioPharma (TASE: CFBI) focussed on ophthalmic disorders, today presented an update on its clinical developments and strategic plans:

Glaucoma - The company is focused on the development of CF101 for the treatment of glaucoma, with a Phase II study ongoing in Israel and Europe. The company intends to amend the ongoing Phase II study protocol and continue to the second cohort, where patients will be treated with 2mg CF101 or placebo.

This decision is based on positive data from the psoriasis Phase II/III study currently conducted with CF101 by Can-Fite BioPharma. As a result, there will not be an interim analysis and the full study data is expected to be announced in mid-2015. If successful, the treatment of glaucoma with an oral drug has the potential to be a breakthrough treatment in resolving patient compliance issues with current topical treatments. A third-party validation for the utilization of A3 adenosine receptor agonists for lowering intraocular pressure and treating glaucoma has been recently published by M Francesca Cordeiro, a professor of glaucoma and retinal neuro-degeneration at the University College of London and Imperial College in London, UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK